POLE and neoplasm: Cancers with mutations in POLE and POLQ (E/Q), POLE and POLZ/REV3L (E/Z) and in all 3 polymerases (E/Q/Z) were associated with the highest mutation burden and an excellent prognosis independent of MSI status and tumor stage.